Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
Bayigga L, Nabatanzi R, Sekiziyivu PN, Mayanja-Kizza H, Kamya MR, Kambugu A, Olobo J, Kiragga A, Kirimunda S, Joloba M, Nakanjako D. Bayigga L, et al. Among authors: nakanjako d. BMC Immunol. 2014 Jan 31;15:2. doi: 10.1186/1471-2172-15-2. BMC Immunol. 2014. PMID: 24483185 Free PMC article.
CD4 T-cell activation and reduced regulatory T-cell populations are associated with early development of cataracts among HIV-infected adults in Uganda.
Nakanjako D, Otiti-Sengeri J, Ssewanyana I, Nabatanzi R, Bayigga L, Kirimunda S, Joloba M, Manabe YC, Kambugu A, Colebunders R, Mayanja-Kizza H. Nakanjako D, et al. Immunol Lett. 2014 Sep;161(1):44-9. doi: 10.1016/j.imlet.2014.04.011. Epub 2014 Apr 28. Immunol Lett. 2014. PMID: 24785834 Free PMC article.
Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.
Nabatanzi R, Bayigga L, Ssinabulya I, Kiragga A, Kambugu A, Olobo J, Joloba M, Kamya MR, Mayanja-Kizza H, Nakanjako D. Nabatanzi R, et al. Among authors: nakanjako d. Immunol Lett. 2014 Dec;162(2 Pt B):264-72. doi: 10.1016/j.imlet.2014.09.016. Epub 2014 Sep 26. Immunol Lett. 2014. PMID: 25263953 Free PMC article. Clinical Trial.
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, Kaleebu P, Kambugu AD, Kamya MR, Sekaly R, Elliott A, Mayanja-Kizza H. Nakanjako D, et al. Trop Med Int Health. 2015 Mar;20(3):380-90. doi: 10.1111/tmi.12442. Epub 2015 Jan 6. Trop Med Int Health. 2015. PMID: 25441397 Free PMC article. Clinical Trial.
Global health leadership training in resource-limited settings: a collaborative approach by academic institutions and local health care programs in Uganda.
Nakanjako D, Namagala E, Semeere A, Kigozi J, Sempa J, Ddamulira JB, Katamba A, Biraro S, Naikoba S, Mashalla Y, Farquhar C; Afya Bora Consortium members; Sewankambo N. Nakanjako D, et al. Hum Resour Health. 2015 Nov 18;13:87. doi: 10.1186/s12960-015-0087-2. Hum Resour Health. 2015. PMID: 26581196 Free PMC article.
109 results